Technological progress in basic medical research and our knowledge of human diseases are constantly increasing. The translation of research results into new therapies is not. Industry and academia agree that new approaches in preclinical research are needed to make results reproducible and finally applicable for the benefit of patients.
The BioMed X Institute, located at the biomedical innovation hub in Heidelberg, Germany, enables a completely new way to accelerate the pace of innovation at which biomedical challenges in preclinical research are tackled: The combination of active global crowdsourcing of the best research talents with local incubation at the campus environment of the University of Heidelberg in Southern Germany.
A Partnership with BioMed X Institute offers you:
- The ideal combination of free, creative, curiosity-driven research with a solid validation of results, timelines and deliverables
- The outsourcing of preclinical research in high-risk exploratory fields
- A cost-effective solution with a clear exit strategy based on IP ownership and transfer of all data and materials
- Internalization of successfully finished research projects into any development pipeline
- Access to the best academic research talent via BioMed X’s crowdsourcing platform
- The opportunity to gather novel ideas from the Global Scientific Community
- A collaborative working model, focused on clear deliverables and constant progress leveraging partners´expertise
- Benefit from the open-innovation lab facility on the campus of the University of Heidelberg
- Easy communication with team, reagent and expertise sharing with monthly update calls, ad hoc calls, Joint Steering Committees progress reports twice per year
Our Partners at a glance
AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 30.000 people worldwide and markets medicines in more than 175 countries. AbbVie is represented in Germany with headquarters in Wiesbaden and a research and production site in Ludwigshafen. In total, AbbVie Germany has about 2.600 employees.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 50.000 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim’s successes in research and development continuously strengthen its portfolio of medications and offer patients true therapeutic benefit. The company’s research focuses on four areas of strength: Immunology and respiratory diseases, cardiometabolic diseases, diseases of the central nervous system, and oncology. With its research functions “Scientific Platforms” and “Research Beyond Borders”, Boehringer Ingelheim is prepared to leverage synergies by investigating scientific concepts with potential in more than one disease area and by exploring emerging science and technology, both within and outside the current research therapeutic focus of Boehringer Ingelheim.
Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. The company strives to create a world without disease and works to make that future a reality for patients everywhere by fighting sickness with science. Janssen’s focus is on areas of medicine such as Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Johnson & Johnson is working to accelerate scientific innovation at all stages of development worldwide in order to deliver cutting-edge solutions for patients’ unmet needs. Johnson & Johnson provides scientists, entrepreneurs and emerging companies with one-stop access to the broad resources of the Johnson & Johnson family of companies across the pharmaceutical, medical devices and consumer healthcare segments.
The biopharmaceutical division of Merck, headquartered in Darmstadt, Germany, offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, and endocrine and metabolic disorders, as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck. Merck discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin for specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of Neurology, Oncology, Immuno-Oncology and Immunology.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and is a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapeutics. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.